Arvinas Holding Company recently held its earnings call, revealing a balanced sentiment among stakeholders. The company showcased strong clinical progress and significant collaborations, notably with ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...